Telomir Pharmaceuticals Business Summary

Telomir Pharmaceuticals, Inc. (TELO) is a preclinical-stage biotechnology company specializing in the development of Telomir-1, a novel small molecule designed to lengthen telomeres and regulate metal ion reactivity to reverse biological aging and treat degenerative diseases. The company employs a dual-market revenue model targeting both human therapeutics—addressing conditions like Progeria, Wilson’s disease, and age-related macular degeneration—and the high-growth veterinary market for geriatric canine longevity. Currently pre-revenue, Telomir generates value through the advancement of its intellectual property pipeline, aiming for future monetization via licensing, strategic biopharma partnerships, and commercial drug sales. Within the longevity and rare disease sectors, Telomir competes with firms such as Milestone Pharmaceuticals, Oncocyte, ProQR Therapeutics, and Acumen Pharmaceuticals, distinguishing itself through its specific focus on epigenetic telomere restoration and metal-ion-mediated inflammation. Originally co-founded by the late Dr. Christopher C. Chapman Jr., the company is currently led by Chairman and CEO Erez Aminov, a biotech and finance veteran who also serves as the CEO of MIRA Pharmaceuticals. The executive team includes Chief Financial Officer Alan Weichselbaum, who brings over 30 years of capital markets experience, and Chief Scientific Advisor Dr. Itzchak Angel, an industry expert with a 40-year track record in pharmaceutical development. The company’s strategic direction is further supported by Senior Advisor Dr. Francis E. O’Donnell Jr. and a board of directors featuring Dr. Matthew P. Del Giudice, Ned MacPherson, and Matthew Pratt Whalen. Notable institutional backing includes significant positions held by Starwood Property Trust, Bayshore Trust, and MIRA Pharmaceuticals, Inc., underscoring the company's integration within the broader life sciences investment ecosystem.